Abstract
Background: Siponimod, an oral, selective sphingosine-1-phosphate (S1P15) receptor modulator, showed efficacy/safety recently in secondary progressive MS (phase 3 expand) and previously in relapsing MS (phase 2 bold) populations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
